Literature DB >> 27286897

The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria.

Hao Li1,2, Matthew Bogyo1, Paula C A da Fonseca3.   

Abstract

Plasmodium falciparum is the parasite responsible for the most severe form of malaria. Its increasing resistance to existing antimalarials represents a major threat to human health and urges the development of new therapeutic strategies to fight malaria. The proteasome is a protease complex essential in all eukaryotes. Accordingly, inhibition of the Plasmodium 20S proteasome is highly toxic for the parasite at all of its infective and developmental stages. Proteasome inhibitors have antimalarial potential both as curative and transmission blocking agents, but in order to have therapeutic application, they must specifically target the Plasmodium proteasome and not its human counterpart. X-ray crystallography has been widely used to determine structures of yeast and mammalian 20S proteasomes with ligands. However, crystallisation of the Plasmodium proteasome is challenging, as only small quantities of the complex can be directly purified from the parasite. Furthermore, most X-ray structures of proteasome-inhibitor complexes require soaking of crystals with high concentrations of ligand, thus preventing analysis of inhibitor subunit specificity. Instead we chose to determine the Plasmodium falciparum 20S proteasome structure, in the presence of a new rationally designed parasite-specific inhibitor, by high-resolution electron cryo-microscopy and single particle analysis. The resulting map, at a resolution of about 3.6 Å, allows a direct molecular analysis of inhibitor/enzyme interactions. Here we present an overview of this structure, and how it provides valuable information that can be used to assist in the design of improved proteasome inhibitors with the potential to be developed as next-generation antimalarial drugs.
© 2016 Federation of European Biochemical Societies.

Entities:  

Keywords:  zzm321990Plasmodiumzzm321990; cryo-EM; drug design; electron microscopy; inhibitor; malaria; proteasome; single particle; structure

Mesh:

Substances:

Year:  2016        PMID: 27286897      PMCID: PMC5140733          DOI: 10.1111/febs.13780

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  22 in total

Review 1.  20S proteasome and its inhibitors: crystallographic knowledge for drug development.

Authors:  Ljudmila Borissenko; Michael Groll
Journal:  Chem Rev       Date:  2007-02-23       Impact factor: 60.622

Review 2.  Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting.

Authors:  Aaron Ciechanover
Journal:  Bioorg Med Chem       Date:  2013-02-08       Impact factor: 3.641

3.  Biochemistry. The resolution revolution.

Authors:  Werner Kühlbrandt
Journal:  Science       Date:  2014-03-28       Impact factor: 47.728

4.  Rational Design of Proteasome Inhibitors as Antimalarial Drugs.

Authors:  Camille Le Chapelain; Michael Groll
Journal:  Angew Chem Int Ed Engl       Date:  2016-04-15       Impact factor: 15.336

5.  Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity.

Authors:  Hao Li; Elizabeth L Ponder; Martijn Verdoes; Kristijana H Asbjornsdottir; Edgar Deu; Laura E Edgington; Jeong Tae Lee; Christopher J Kirk; Susan D Demo; Kim C Williamson; Matthew Bogyo
Journal:  Chem Biol       Date:  2012-11-08

Review 6.  Covalent and non-covalent reversible proteasome inhibition.

Authors:  Philipp Beck; Christian Dubiella; Michael Groll
Journal:  Biol Chem       Date:  2012-10       Impact factor: 3.915

7.  Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution.

Authors:  J Löwe; D Stock; B Jap; P Zwickl; W Baumeister; R Huber
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

8.  Spread of artemisinin resistance in Plasmodium falciparum malaria.

Authors:  Elizabeth A Ashley; Mehul Dhorda; Rick M Fairhurst; Chanaki Amaratunga; Parath Lim; Seila Suon; Sokunthea Sreng; Jennifer M Anderson; Sivanna Mao; Baramey Sam; Chantha Sopha; Char Meng Chuor; Chea Nguon; Siv Sovannaroth; Sasithon Pukrittayakamee; Podjanee Jittamala; Kesinee Chotivanich; Kitipumi Chutasmit; Chaiyaporn Suchatsoonthorn; Ratchadaporn Runcharoen; Tran Tinh Hien; Nguyen Thanh Thuy-Nhien; Ngo Viet Thanh; Nguyen Hoan Phu; Ye Htut; Kay-Thwe Han; Kyin Hla Aye; Olugbenga A Mokuolu; Rasaq R Olaosebikan; Olaleke O Folaranmi; Mayfong Mayxay; Maniphone Khanthavong; Bouasy Hongvanthong; Paul N Newton; Marie A Onyamboko; Caterina I Fanello; Antoinette K Tshefu; Neelima Mishra; Neena Valecha; Aung Pyae Phyo; Francois Nosten; Poravuth Yi; Rupam Tripura; Steffen Borrmann; Mahfudh Bashraheil; Judy Peshu; M Abul Faiz; Aniruddha Ghose; M Amir Hossain; Rasheda Samad; M Ridwanur Rahman; M Mahtabuddin Hasan; Akhterul Islam; Olivo Miotto; Roberto Amato; Bronwyn MacInnis; Jim Stalker; Dominic P Kwiatkowski; Zbynek Bozdech; Atthanee Jeeyapant; Phaik Yeong Cheah; Tharisara Sakulthaew; Jeremy Chalk; Benjamas Intharabut; Kamolrat Silamut; Sue J Lee; Benchawan Vihokhern; Chanon Kunasol; Mallika Imwong; Joel Tarning; Walter J Taylor; Shunmay Yeung; Charles J Woodrow; Jennifer A Flegg; Debashish Das; Jeffery Smith; Meera Venkatesan; Christopher V Plowe; Kasia Stepniewska; Philippe J Guerin; Arjen M Dondorp; Nicholas P Day; Nicholas J White
Journal:  N Engl J Med       Date:  2014-07-31       Impact factor: 91.245

9.  Measuring the optimal exposure for single particle cryo-EM using a 2.6 Å reconstruction of rotavirus VP6.

Authors:  Timothy Grant; Nikolaus Grigorieff
Journal:  Elife       Date:  2015-05-29       Impact factor: 8.140

10.  Structure- and function-based design of Plasmodium-selective proteasome inhibitors.

Authors:  Hao Li; Anthony J O'Donoghue; Wouter A van der Linden; Stanley C Xie; Euna Yoo; Ian T Foe; Leann Tilley; Charles S Craik; Paula C A da Fonseca; Matthew Bogyo
Journal:  Nature       Date:  2016-02-11       Impact factor: 49.962

View more
  7 in total

1.  Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors.

Authors:  Euna Yoo; Barbara H Stokes; Hanna de Jong; Manu Vanaerschot; Trs Kumar; Nina Lawrence; Mathew Njoroge; Arnold Garcia; Renier Van der Westhuyzen; Jeremiah D Momper; Caroline L Ng; David A Fidock; Matthew Bogyo
Journal:  J Am Chem Soc       Date:  2018-08-29       Impact factor: 15.419

2.  Development of a Potent Inhibitor of the Plasmodium Proteasome with Reduced Mammalian Toxicity.

Authors:  Gregory M LaMonte; Jehad Almaliti; Betsaida Bibo-Verdugo; Lena Keller; Bing Yu Zou; Jennifer Yang; Yevgeniya Antonova-Koch; Pamela Orjuela-Sanchez; Colleen A Boyle; Edgar Vigil; Lawrence Wang; Gregory M Goldgof; Lena Gerwick; Anthony J O'Donoghue; Elizabeth A Winzeler; William H Gerwick; Sabine Ottilie
Journal:  J Med Chem       Date:  2017-07-25       Impact factor: 7.446

3.  High-resolution cryo-EM proteasome structures in drug development.

Authors:  Edward P Morris; Paula C A da Fonseca
Journal:  Acta Crystallogr D Struct Biol       Date:  2017-05-31       Impact factor: 7.652

4.  Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.

Authors:  Barbara H Stokes; Euna Yoo; James M Murithi; Madeline R Luth; Pavel Afanasyev; Paula C A da Fonseca; Elizabeth A Winzeler; Caroline L Ng; Matthew Bogyo; David A Fidock
Journal:  PLoS Pathog       Date:  2019-06-06       Impact factor: 6.823

Review 5.  The genomic architecture of antimalarial drug resistance.

Authors:  Annie N Cowell; Elizabeth A Winzeler
Journal:  Brief Funct Genomics       Date:  2019-09-24       Impact factor: 4.241

Review 6.  Hotspots in Plasmodium and RBC Receptor-Ligand Interactions: Key Pieces for Inhibiting Malarial Parasite Invasion.

Authors:  Manuel Alfonso Patarroyo; Jessica Molina-Franky; Marcela Gómez; Gabriela Arévalo-Pinzón; Manuel Elkin Patarroyo
Journal:  Int J Mol Sci       Date:  2020-07-02       Impact factor: 5.923

7.  Validation of Babesia proteasome as a drug target.

Authors:  Marie Jalovecka; David Hartmann; Yukiko Miyamoto; Lars Eckmann; Ondrej Hajdusek; Anthony J O'Donoghue; Daniel Sojka
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-08-07       Impact factor: 4.077

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.